U.S. Markets closed

OncoCyte Corporation (OCX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.7900+0.0600 (+3.47%)
At close: 1:00PM EST
Sign in to post a message.
  • X
    Xonder
    DetermaRx sales seem small relative to the market cap.
    Neutral
  • C
    Chris
    KeyBanc analyst Paul Knight initiated coverage of OncoCyte with an Overweight rating and $5 price target. OncoCyte has gone from a pre-commerical and pre-revenue diagnostic company to one that is commercial and now generating revenue with its recent CMS approval of DetermaRx, noted Knight, who thinks that multiple expansion is warranted as revenue builds and the company sees traction in its commercial efforts
  • C
    Chris
    Piper Sandler analyst Steven Mah raised the firm's price target on OncoCyte to $2 from $1.50 and keeps a Neutral rating on the shares following the company's Q3 results. The initial DetermaRx commercial launch is showing "encouraging" early adoption with 175 billable tests and 67 hospital sites onboarded in Q3, Mah tells investors in a research note.
    Bullish
  • b
    bill
    I was in this stock, but got out recently in the 1.90 area. Stock has a future , but will probably face dilution first as it has significant cash burn. Would consider buying on a significant dip. Probably needs a few thousand tests a quarter to break even. Need a while for that to happen.
  • B
    BejingJoe
    Padma Sundar, Senior Vice President, Commercial at Oncocyte, commented, “Coming off a very strong third quarter (during which we received final Medicare pricing within our expected range, and saw DetermaRx order volumes more than double from the second quarter), we are extremely excited about the release of the new prospective data. We believe these data expand the utility of DetermaRx for both chemotherapy and targeted therapy selection, ultimately facilitating continued rapid market adoption.
    Bullish
  • C
    Cody
    I think this will fly fast with a decisive breakthrough above today’s high of $1.68
    Bullish
  • B
    BejingJoe
    I meant to say they don't sell anything yet but they large prospects for a small company. They only issue a small amount of shares to finance operations. The stock will be worth 10x once they formally publish the data for the lung cancer test! Buy now before the conference on Oct 22!
    Bullish
  • k
    kc
    Not bad. Huge volume and didn't sell off.
  • B
    BejingJoe
    This will recover during afternoon trading and move up AH
    Bullish
  • S
    Steven
    Looks good today. Positive news for lung cancer. We need this.
    Bullish
  • K
    KiwiBrit
    OncoCyte's DetermaRx testing volumes more than doubled in Q3
    Stock Market Insights | Seeking Alpha
    seekingalpha.com
  • E
    Eddie78
    There just 67 mill outstanding with 30 mil controlled by insiders - others are manipulating this stock - the best is yet to come sales out i11/11
  • M
    Max
    Waiting on upgrades to come !
  • E
    Eddie78
    Ocx should be like 3 bucks now the sales are growing
  • B
    BejingJoe
    Love this stock at this level
    Bullish
  • B
    BejingJoe
    "High-risk status as identified by the DetermaRx test was used to inform the use of adjuvant chemotherapy, and strikingly, 94% of patients who selected adjuvant chemotherapy were cancer-free after five years of follow-up. In contrast, one in three high-risk patients who elected to forego chemotherapy had a recurrence."
    Bullish
  • K
    KiwiBrit
    Treatment informed by Oncocyte's DetermaRx improves survival in lung cancer patients
    Stock Market Insights | Seeking Alpha
    seekingalpha.com
  • M
    Mark
    this has consolidated and now ready to make another run, probably leaked news volume picking up
  • C
    Colour Number
    +17.17% AH. Any news?
  • B
    BejingJoe
    Lung cancer is VERY REAL! OCX is VERY relevant in the lung cancer diagnostic space.
    Bullish